A semi-automatic method for delineating contrast-agent enhancing brain tumor, called quantitative delta T1 (qDT1), was compared to central reader analysis of clinical trial data. The qDT1 method demonstrated equivalence with expert reads for determination of early tumor progression and proved superior for further distinguishing responders from non-responders/non-progressors at the week 8 time point. Using qDT1 provides a solution to the high percentage of intra- and inter-observer disagreements, while being easier to use and more reliable for the daily clinical assessment of tumor response to therapy, as well as for large scale clinical trials.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords